




**FIG. 1A**



- ❖ The ring comprises at least one fatty acid substituent between C₆ and C₁₂, e.g., C₈, and at least two polar group substituents, wherein:
 - ❖ At least one of R1..R5 comprises or consists of a halogen group (e.g., F, Cl, or Br)
 - ❖ At least one of R1..R5 comprises or consists of an OH group
- ❖ At least two of R1..R5 are not H
- ❖ X1 to X5 are alkyl spacers, e.g., CH₂, wherein n is independently between 0 and 5

FIG. 1B



SUBSTITUTE SHEET (RULE 26)

FIG. 2







FIG. 3

**FIG. 3**

**FIG. 4**

SUBSTITUTE SHEET (RULE 26)

**FIG. 4**

SUBSTITUTE SHEET (RULE 26)




FIG. 5




FIG. 6




FIG. 7




FIG. 8

Dose group	End of dosing (µg/gram tissue)	End of recovery (µg/gram tissue)
SQ Q2W x 3	33.8 (19.1)	N.A.
1 capsule QD x 42	2.3 (1.2)	0.6 (0.2)
2 capsules QD x 42	4.0 (1.6)	0.9 (0.7)

FIG. 9




FIG. 10




FIG. 11A




FIG. 11B





FIG. 12



Animals: 10 non-naive HNPs (5m/5F)
PK: at pre-dose & 0.5, 1.5, 3 and 5 hours post dose on dosing days
Clinical observations: Twice weekly
Clinical chemistry: days -7 and end of dosing

FIG. 13





FIG. 14

	No. animals	Mean AUC ₀₋₅ (ng*ml ^{1/2} h)	SD	Mean C _{max} (ng/ml)	SD
CIVI008/SNAC	6	67.1	50.7	50.7	52.3
CIVI008/5-CNAC	10	122.5	98.6	106.9	91.2

FIG. 15



	No. Capsules	No. Animals	Mean AUC ₀₋₅ (ng·ml ² /h)	SD	Mean C _{max} (ng/ml)	SD
Group B	2	10	97.0	87.9	60.8	64.6
Group C	1	10	144.8	101.2	116.9	114.1

FIG. 16




FIG. 17

Dry Blend




FIG. 18A

Freeze Dried




FIG. 18B




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23